PR Newswire All News ReleasesQwen · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 15:30:00·⟳ 抓取 15:30:27 +27s·⚡ 决策 08-31 20:32:21 +5h01m·57.0 天前
律所DJS Law Group发布证券集体诉讼征集公告，指控Capricor Therapeutics在Deramiocel临床数据统计分析计划变更上误导投资者
本事件是律所通过PR Newswire发布的证券集体诉讼征集公告(本质为律师广告)，不是新的基本面催化。底层负面事件——Capricor修改Deramiocel统计分析计划未获FDA同意即重新提交BLA——发生在2025年12月至2026年7月期间，市场早已消化。证券集体诉讼公告在实证中对股价增量影响极小，且该公告本身不改变公司盈利、现金流或业务前景。做空红线不满足：这不是新的强空催化，只是已知问题的法律衍生事件。
📄 原文PR Newswire All News Releases↗ 原文
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAP…
不做 Capricor Therapeutics（CAPR.US）
本事件为律所证券集体诉讼征集公告(律师广告)，非新增基本面信息。底层负面催化(修改统计分析计划未获FDA同意)发生于2025年12月-2026年7月期间，市场早已定价。做空红线不满足：不是新的强空催化，仅是已知问题的法律衍生公告，置信度远低于4。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
DJS Law Group于2026年8月31日发布证券集体诉讼征集公告，指控Capricor在Deramiocel BLA重新提交过程中修改统计分析计划未获FDA同意。但集体诉讼期间为2025年12月至2026年7月，说明底层负面事件已发生数月并被市场定价。律所征集公告是律师广告性质，不构成新增基本面信息，对股价无增量影响。无可交易edge，AVOID。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 high ↗
主要风险
- 证券集体诉讼若最终判决赔偿可能对公司财务造成压力，但这是远期且高度不确定的，不构成短线交易催化
先例如何影响了这次决策
对本次决策的影响:先例研究不必要：律所征集公告不是独立催化事件，不产生可交易的价格反应
方向:证券集体诉讼征集公告对股价增量影响极小，属于已知负面事件的法律衍生
涨幅量级:无需校准幅度，事件本身不构成可交易催化
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 109 ms
{"result": "search_processed_events:agent query=`capr lawsuit deramiocel fda statistical analysis | capricor therapeutics securities class action | djs law group capricor`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.2/72 小时、1063 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 2,208 字
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。